Human papillomavirus vaccines for cervical cancer

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 643-650

  Tindle, Robert W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; VIRUS PROTEIN;

CELL TRANSFORMATION; DISEASE COURSE; HUMAN; PROPHYLAXIS; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0030272323     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80080-X     Document Type: Article

References (63)

1. Heinzel PA, Chan SY, Ho L, O'Connor M, Balaram P, Campo MS, Fujinaga K, Kiviat N, Kuypers J, Pfister H, et al. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sample throughout the world. J Clin Microbiol. 33:1995;1746-1754.
2. Cheng G, Icenogle JP, Kumbauer R, Hubbert NL, St Louis ME, Han C, Svare EI, Kjaer SK, Lowy DR, Schiller JT. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis. 172:1995;1584-1587.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kuman R, Shah KV. Prevalence of human papillomavirus is cervical cancer: a world-wide perspective. International Biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 87:1995;796-802.
4. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kumbauer R, Koskela P, Paavonen J, Peto R, Schiller Jt, Hakama M. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ. 312:1996;537-539.
5. Chua KL, Hjierpa A. Persistance of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer. 77:1996;121-127.
6. Kjaer SK, Van Den Brule AJC, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomer JMM, Meijer CJLM. Human papillomavirus - the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer. 65:1996;601-606.
7. Puranen M, Yliskoski M, Saarikoski S, Syrjanen K, Syrjanen s. Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol. 174:1996;694-699.
8. Wikstrom A, Van Doornum GJ, Kimbauer R, Quint WG, Dillner J. Prospective study on the development of antibodies against papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol. 46:1995;368-374.
9. Dillner L, Zellbi A, Avall-Lundqvist E, Heino P, Eklund C, Petterson CA, Forslund O, Hansson BG, Grandien M, Bistoletti P, et al. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2 and E7 antigens and of HPV DNA with incident cervical cancer. Cancer Detect Prev. 19:1995;381-393.
10. De Sanjosé S, Hamsikova V, Muñoz N, Bosch FX, Hofmannova V, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, et al. Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer. 66:1995;70-74.
11. IH Frazer. Immunology of papillomavirus infection. Curr Opin Immunol. 4:1996;484-491.
12. Tindle RW, Frazer IH. Human papillomavirus infection, genital warts and cerical cancer: prospects for prophylactic and therapeutic vaccines. Exp Opin Invest Drugs. 9:1995;783-797.
13. Münger K. The molecular biology of cervical cancer. J Cell Biochem. 59:1995;55-60. (suppl 23).
14. Christensen ND, Cladel NM, Reed CA. Post-attachment neutralisation of papillomavirus by monoclonal and polyclonal antibodies. of special interest Virology. 201:1995;136-142 Prevention of infection development by the addition of neutralizing antibodies up to eight hours postattachment of PVs to cells suggests that PVs attach to but do not penetrate host cells for a considerable period of time.
15. Heim K, Christensen ND, Hoepfl R, Wartusch B, Pinzger G, Zeimet A, Baugartner P, Kreider JW, Dapunt O. Serum IgG, IgM and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups. J Infect Dis. 172:1995;395-402.
16. Le Cann P, Touze A, Enogat N, Leboulleux D, Mougin C, Legrand MC, Calvet C, Afoutou JM, Coursaget P. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol. 33:1995;1380-1382.
17. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Müller M, Jansen KU. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol. 77:1996;465-468.
18. Heino P, Dillner J, Schwartz S. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology. 214:1995;349-359.
19. Ghim SJ, Young R, Jenson AB. Antigenicity of bovine papillomavirus type 1 (BPV-1) virus-like particles compared with that of intact BPV-1 virions. J Gen Virol. 77:1996;183-188.
20. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. of outstanding interest J Virol. 70:1996;960-965 Two weeks after CRVP-L1 VLP immunization, rabbits were completely protected against virus challenge which, in contrast, produced papillomas in 100% of control immunized rabbits. Protection persisted over 1 year. Serum neutralizing antibody titres declined from 1 in 10 000 to 1 in 100 over this period in immunized but unchallenged rabbits.
21. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trindinh-Desmarquet C, Orth G, Schiller JT, Lowly DR. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 69:1995;3959-3963.
22. Hines JF, Ghim S, Christensen ND, Kreider TW, Barnes WA, Schlegel R, Jenson AB. The expressed L1 proteins of HPV-1, HPV-6 and HPV-11 display type specific epitopes with native conformation and reactivity with neutralising and non-neutralising antibodies. Pathobiology. 62:1994;165-171.
23. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. of outstanding interest Proc Natl Acad Sci USA. 92:1995;1153-11557 Baculovirus expressed recombinant COPV-L1 spontaneously assembles into VLPs which when purified and injected intradermally into the foot pad, rendered beagle dogs completely resistant to experimental challenge with COPV. Protection was antibody mediated and could be adoptively transferred to naive recipients. This is important because it shows that intradermal immunization will produce effective viral neutralization at a mucosal surface. There are obvious implications for a prophylactic vaccine for human anogenital mucosal PVs, an infection that can proceed to malignancy.
24. Husband J. Novel development to vaccines for the control of mucosal infection. Exp Opin Invest Drugs. 3:1994;895-906.
25. Martins LP, Lau LL, Asano MS, Ahmed R. DNA vaccination against persistent viral infection. J Virol. 69:1995;2574-2582.
26. Donnelly JJ, Martinez D, Jansen KV, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. of special interest J Infect Dis. 713:1996;314-320 Immunization with plasmid DNA encoding CRPV-L1 protein elicited conformationally specific neutralizing antibodies and provided immunity against papilloma formation upon challenge with CRPV. A similar strategy may protect humans against HPV. By combining plasmids encoding capsid protein of different HPV strains, a protective multivalent vaccine may be achieved.
27. Ruffin MT, Ogaily MS, Johnston CM, Gregoire L, Lancaster WD, Brenner DE. Surrogate endpoint biomarkers for cervical cancer chemoprevention trials. J Cell Biochem. 23:1995;113-124. (suppl 59).
28. Von Knebel Doeberitz H, Rittmuller C, Aengeneydt F, Jansen Durr P, Spitovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for phenotype and E6-p53 and E7-pRB interactions. J Virol. 68:1994;2811-2821.
29. Keating PJ, Cromme Fv, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. of special interest Br J Cancer. 146:1995;944-952 Downregulation of MHC class I molecules and/or TAP proteins was demonstrated in the majority of cancers examined (approximately 100). The implication is that the presentation of PV proteins results in immune selection pressure favouring tumour cells that are usually presentation deficient.
30. + individuals.
31. Bartholomew JW, Stacey SN, Coles B, Burt DJ, Arrand JR, Stern PL. Identification of a naturally processed HLA A0201-restricted viral peptide from cells exp ressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol. 24:1994;3175-3179.
32. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJ, Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type E6 and E7 proteins. J Immunol. 152:1994;3904-3912.
33. Feltkamp MC, Vierboom MP, Toes RE, Ossendorp F, Ter-Schegget J, Melief CJ, Kast WM. Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. of special interest Immunol Lett. 47:1995;1-8 A newly described peptide competition cytotoxicity assay based on inhibition of CTL lysis by competition between a known CTL epitope and a peptide of interest is likely to identify high affinity MHC class I binding `dominant' epitopes for inclusion in HPV16 E6 and E7 subunit vaccines.
34. Feltkamp MC, GR Vreugdenhil, Vierboom MP, Ras E, Van Der Burg SH, Ter-Schegget J, Melief CJ, Kast WM. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. of special interest Eur J Immunol. 25:1995;2638-2642 Immunization with a synthetic subdominant epitope-containing peptide led to induction of CTLs that controlled a HPV16 E7-containing tumour.
35. + cytotoxic T-cells: implications for vaccine design. of outstanding interest Proc Natl Acad Sci USA. 13:1995;5845-5849 A polypeptide consisting of nine CTL epitopes linked without flanking sequences was processed in vivo and presented appropriately to the nine corresponding CTL clones. There are implications for the construction of a HPV 16 E7/E6 polyepitope vaccine that is functional in the context of multiple MHC class I haplotypes.
36. Dranoff G, Jaffee E, Lazenby A, Golumbe KP, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent specific and long-lasting anti-tumour immunity. Proc Natl Acad Sci USA. 90:1993;3593-3543.
37. Greenberg PL, Watanabe K, Gilbert M, Nelson B, Riddell S. Reconstitution of viral immunity in immunocompromised humans by adoptive transfer of T-cell clones. J Cell. 17:1993;99-105. (suppl 1).
38. Riddell SR, Elliott M, Lewinston DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overall RW, Reynolds TC, Corey L, Greenberg PD. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 2:1996;216-223.
39. + of HPV16 E7 by targeting a chimeric E7/LAMP-1 protein expressed in vaccinia virus to the endosomal and lysozomal compartments. Mice immunized with recombinant-vaccinia E7/LAMP-1 showed augmented antibody and CTL responses compared with mice immunized with recombinant vaccinia E7.
40. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky H, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. of outstanding interest Cancer Res. 56:1996;21-26 This paper extends the work reported in [46] into the in vivo situation. Immunization of mice with recombinant vaccinia E7/LAMP-1 conveyed enhanced protection against a E7-containing epithelial tumour challenge and in small-tumour-bearing mice it induced remission. Little effect was seen by immunization with recombinant vaccinia E7. This underscores the importance of appropriate with recombinant vaccinia E7. This underscores the importance of appropriate presentation of vaccine antigen and how it may be maximized by rerouting antigen into the MHC class II associated processing machinery. The findings also expose the limitations of recombinant vaccinia exp ressing unmodified tumour antigens.
41. Ossevoort MA, Feltkamp MCW, Van Veen KJH, Melief CJM, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumour. of special interest J Immunother. 18:1995;86-94 This paper demonstrates the principle of the induction of an enhanced immune response by antigen-pulsed dendritic cells as applied to a CTL epitope of HPV16.
42. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1:1996;52-58.
43. Routes JM, Ryan S. Oncogenicity of human papillomavirus for adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. J Virol. 69:1995;7639-7647.
44. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and Interleukin-6 soluble receptor regulate proliferation of normal human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. of special interest Am J Pathol. 146:1995;944-952 IL-6 stimulates the proliferation of HPV immortalized cervical cells via an epidermal growth factor (EGF) receptor-dependent pathway involving autocrine stimulation by transforming growth factor (TGF)-α and amphiregulin. Blockage of this pathway is a possible strategy for HPV-induced cervical dysplasia.
45. Ramsay AJ, Leong KH, Boyle D, Ruby J, Ramshaw IA. Enhancement of mucosal IgA responses by interleukins 5 and 6 encoded in recombinant vaccine vectors. Reprod Fertil Dev. 4:1994;389-392.
46. Zhu X, Tommasino M, Vousden K, Sadovnikava F, Rappuoli R, Crawford L, Kast M, Melief CJ, Beverley PC, Stauss HJ. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. of special interest J Immunol. 47:1995;557-563 Immunization of mice with either a vaccinia-E7 recombinant, or E7 protein in MF59 adjuvant, stimulated CTLs with similar fine specificity for E7. This observation is meaningful when considering delivery strategies for E7-mediated therapeutic vaccines in humans.
47. 2- responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol. 101:1995;265-271.
48. Londono LP, Chatfield S, Tindle RW, Herd K, Gao X-M, Frazer I, Dougan G. Immunization of mice using Salmonella typhimurium expressing human papillomavirus 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine. 1996;. in press.
49. Oggioni MR, Manganelli R, Contorni M, Tommasino M, Pozzi G. Immunization of mice by oral colonization with live recombinant commensal streptococci. Vaccine. 13:1995;775-779.
50. Frazer IH, Lieppe DM, Dunn LA, Liem A, Tindle RW, Fernando GJP, Phelps WC, Lambert PF. Immunological responses in HPV16 E6-E7 transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55:1995;2635-2639.
51. Chambers MA, Wei Z, Coleman N, Nash AA, Stanley MA. `Natural' presentation of human papillomavirus type 16 E7 protein to immunocompetent mice results in antigen-specific sensitisation or sustained unresponsiveness. Eur J Immunol. 24:1994;738-745.
52. Sexton CJ, Williams AT, Topley P, Shaw RJ, Lovegrove C, Leigh I, Stables JN. Development and characterization of a novel xenograft model permissive for human papillomavirus DNA amplification and late gene expression. J Gen Virol. 76:1995;3107-3112.
53. of outstanding interest Boursnell MEG, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Boryslewicz LK, Vousden K, Inglis SC. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. of special interest Vaccine. 1995; This article describes the recombinant vaccinia E6/E7 construct used in the UK clinical trial [54].
54. Borysiewicz LK, Flander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans A, Adams M, Stacey SN, Boursnell MEG, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. of outstanding interest Lancet. 347:1996;1523-1527 The clinical and environmental safety and the immunogenicity of a live recombinant vaccinia virus expressing HPV16 and 18 E6/E7 fused-ORF mutated to abrogate retinoblastoma protein binding was demonstrated in cervical carcinoma patients.
55. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth P, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA A*0201 binding peptides. of special interest J Immunol. 154:1995;5934-5943 HLA A*0201 restricted CTL epitopes identified in HPV16 E7 protein are candidates for inclusion in a therapeutic vaccine for cervical cancer.
56. Ressing ME, Van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, Schreuder GMT, Term Harmsel WB, Fleuren GJ, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201 restricted E7-encoded epitope. of outstanding interest Cancer Res. 56:1996;582-588 Detecting CTL precursors, where they exist, is essentially a numbers game. This paper demonstrates that at least some HLA A*0201 cervical carcinoma patients have detectable CTL precursors directed to a defined CTL epitope of HPV16 E7. Since such precursors were not detected in normal HLA A*0201 individuals (but presumably exist below the level of detection, although not necessarily in all individuals), the implication is that E7 is presented by tumours and expands the E7 CTL population. This suggests that the likelihood that vaccination with E7 would induce or augment an E7 CTL response in at least some patients.
57. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol. 69:1995;3185-3192.
58. Brown DR, Bryan JT, Pratt L, Handy V, Fife KH, Stoler MH. Human papillomavirus type 11 E1-E4 and L1 proteins colocalize in the mouse xenograft system at multiple time points. Virology. 214:1995;259-263.
59. Wilke CM, Hall BK, Hodge A, Paradee W, Smith DI, Glover TW. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet. 5:1996;187-195.
60. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 69:1995;2989-2997.
61. Xiong Y, Kuppuswamy D, Li Y, Livanos EM, Hixon M, White A, Beach D, Tisty TD. Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. J Virol. 70:1996;999-1008.
62. McIntyre MC, Ruesch MN, Laimins LA. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with Cdk2 and p107. Virology. 215:1996;73-82.
63. Mullokandov MR, Kholodilov NG, Atkin NB, Burk Rd, Johnson AB, Linger HP. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papillomavirus tumour status. Cancer Res. 56:1996;197-205.